As MS Rises In The Arab World, Dubai Hosts First Multiple Sclerosis Conference In The Region

admin avatar

by admin |

Share this article:

Share article via email

DubaiThe Middle East North Africa Committee for Treatment and Research in Multiple Sclerosis has recently announced the first MENACTRIMS Congress for professionals to be held in Dubai on the 17th and 18th of October.

While Multiple Sclerosis (MS) is often associated with North America and Northern Europe, the disease has been continuously rising in Arab world over the last 20 years and studies suggest that its prevalence is now ten times higher in Kuwait, four in Saudi Arabia, and twice more in Jordan.

In response to this, the need to provide the best treatment and the development of research for the disease led to the organization of the event. “Multiple Sclerosis has recently entered a new area with noteworthy treatment advances and new understanding of the disease,” said Dr. Bassem I. Yamout, president of MENACTRIMS, professor of clinical neurology and director of the Multiple Sclerosis Center Clinical Research, who also noted that the know-how of the professionals in the region is of great importance to ensure “that patients get the most optimal treatment.”

The congress will gather more than 500 professionals, mostly neurologists, healthcare professionals, and researchers, who will focus on recent discoveries and advances in MS, such as new therapeutic strategies, neuroimaging, epidemiology, risk factors (genetic and environmental), diagnosis, and management of the disease, etc.

[adrotate group=”4″]

According to the organization, the goals of the event are to present the latest advances in MS pathogenesis, explain the role of genetic and environmental factors in the disease, improve its diagnosis, identify the main predictors of disease progression, highlight emerging therapies and new MRI techniques to diagnose and monitor disease activity, and develop new treatment strategies in MS.

MENACTRIMS is an independent organization focused on promoting and improving clinical outcomes in MS.